High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours
详细信息 查看全文
- 作者：Grace Kong ; Jason Callahan…
- 关键词：Neuroendocrine ; Yttrium ; Lutetium ; Octreotate ; Radionuclide therapy ; Peptide receptors
- 刊名：European Journal of Nuclear Medicine and Molecular Imaging
- 出版年：2017
- 出版时间：March 2017
- 年：2017
- 卷：44
- 期：3
- 页码：476-489
- 全文大小：
- 刊物类别：Medicine
- 刊物主题：Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology;
- 出版者：Springer Berlin Heidelberg
- ISSN：1619-7089
- 卷排序：44
文摘
PurposeBulky disease is an adverse prognostic factor for 177Lu-DOTA-octreotate (177Lu-DOTATATE) peptide receptor radionuclide therapy (PRRT). 90Y-DOTA-octreotate (90Y-DOTATATE) has theoretical advantages in this setting but may less effectively treat co-existent smaller deposits and have higher toxicity than 177Lu-DOTATATE. The aim of this study was to assess the efficacy and safety of using these agents sequentially.